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Abstract
Background: The International Lymphedema Framework developed an international study, Lymphedema
Impact and Prevalence International (LIMPRINT), to estimate the prevalence and impact of chronic edema
(CO) in heterogeneous populations.
Methods and Results: A validation study using the LIMPRINT methodology was undertaken in Denmark.
Participants with CO were identified from inpatient services and compared with those identified within a specialist
lymphedema service and three primary care settings. Of 452 inpatients available for screening, CO was present in
177 (39%) and absent in 275 (61%). In addition, 723 participants were found from specialist and primary care
services (LPCSs). Inpatients were significantly older and more likely to be underweight or normal weight. They
were more likely to suffer from heart failure/ischaemic heart disease (44.6% vs. 23.4%, p<0.001) and have
neurological problems (18.1% vs. 10.9% p=0.009). Patients in the inpatient group were nearly all suffering from
secondary lymphedema and were less likely to have a cancer or venous diagnosis, but more likely to have
immobility as the cause of CO (44.0% vs. 17.7%, p<0.001). No inpatients had midline CO compared with 30
within LPCSs. Fewer in the inpatient group had standard CO treatment (17.1% vs. 73.5%, p< 0.001) and subjective
control of swelling was worse (19.9% vs. 66.7%, p<0.001). While the inpatient group experienced fewer acute
infections, when they did so, they were more likely to be admitted to hospital for this (78.6% vs. 51.0%, p=0.049).
Conclusion: The prevalence of CO in inpatient facilities is high and those with CO have multiple comorbidities
that vary according to setting. The feasibility study showed that the methodology could be adapted for use in
different health systems.
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Introduction
Chronic Edema (CO) is a common health problem thathas received scant attention in health care systems de-
spite its impact on the patient. Internationally, the terminol-
ogy, CO, has now been adopted to replace the term
lymphedema, which implies that it is only related to a lym-
phatic problem. CO has been developed as a public health
term to capture the wide range of patients affected, which
includes patients with primary lymphedema as well as those
with a range of secondary forms. The term CO indicates
chronic swelling for at least 3 months, irrespective of the
underlying etiology.1
The correlation between CO and cancer is well docu-
mented within prevalence and incidence studies. A meta-
analysis concluded that 20% of women surviving breast
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cancer will develop breast cancer-related CO despite recent
improvements in treatment such as sentinel node biopsy.2
The perception that CO is purely related to cancer has now
changed, and it is recognized that secondary forms of CO
may affect many patients and this study aims to examine this
in more detail. In the original study using the definition of
CO, the authors found that the overall prevalence was 1.3 per
1000 rising to 10.3 per 1000 in the elderly in the health care
population, indicating a strong association with age.1 More
recently, a study using the same methods indicated that the
prevalence had risen to nearly 4/1000.3 It is known that there
is a strong correlation between obesity and CO, although
robust studies on this are required to establish the true size of
the problem and understand the mechanisms causing CO.4
It has been shown that CO has a significant impact on the
individual, families, and the health care system.5 CO most fre-
quently affects limbs and is associated with pain, reduced mo-
bility, and complications such as cellulitis and wounds, which
may require hospitalization. Untreated, the condition can lead to
elephantiasis where the limb increases drastically in size with
significant tissue changes. It is predicted that CO will increase in
the coming years because of higher average life expectancy,
higher cancer survival rates, and increase in levels of obesity.6
Changes in demographics in both Western and Asian popula-
tions indicate that the human and economic costs of CO and its
complications will be a much larger health problem in the future.
As in other countries, knowledge about the size of the problem
in Denmark, the types of patients affected, and the impact it has
on patients and the health care system are unknown.
This study formed part of an international epidemiology
study, Lymphedema Impact and Prevalence International
(LIMPRINT), to define the prevalence and impact of CO in
health services in different countries and health care systems.
This study was the initial validation project undertaken fol-
lowing development of the study methodology.
To understand the current scale of the problem within
health services in Copenhagen, Denmark, and to explore the
feasibility of using the LIMPRINT methodology, the study
was designed with three related aims:
 to determine the prevalence of CO within a range of
health care settings in Copenhagen, including two
hospital inpatient services, patients treated in a spe-
cialist lymphedema clinic (acute care based), and three
primary care settings,
 to compare profiles of patients identified in different
settings, and
 to explore the feasibility of undertaking the study to
inform the wider implementation of LIMPRINT during
the international roll-out phase.
The study used the following patient inclusion and ex-
clusion criteria:
Inclusion
 Patients over 18 years of age who had CO for more
than 3 months
 Able to understand written information in Danish
 Able to give informed consent to participate in the study
Exclusion
 Patients who did not want to participate
 People under the age of 18 years
 People who did not understand Danish
 Edema present for less than 3 months
Data sets
The development and validation of the LIMPRINT
methodology have been published separately.7 During the
study, the following data were captured using standardized
questionnaires:
 social demographics and care: age, gender, and main
care provider
 presence and site of CO using a body map, details, and
duration of CO, cellulitis history, leg ulceration and
wounds, pitting test, Stemmer’s sign, and soft/hard tissues
 classification of the CO into primary/secondary lym-
phedema and related risk factors
 lower limb mobility status (bedbound, chairbound,
walks with walking aid, or walks unaided)
 upper body mobility (full range of movement, limited
range of movement, or normal function)
 obesity status (underweight, normal weight, obese, or
morbidly obese)
 relevant comorbidities: diabetes mellitus, neurological
disorders, heart failure/ischemic heart disease, or peri-
pheral arterial occlusive disease
 types of treatments received for CO
 subjective control of swelling, access to specialist ser-
vice, and requirements for community care
 details of swelling
As the study documentation was written in English, the
first step involved ensuring an accurate translation into
Danish. This involved translation and back translation of all
study documentation. The data collection tools were then
piloted with 10 patients at the wound healing center by
general nurses to ensure that all questions were easily un-
derstood. Documentation was also completed by specialist
nurses on the same patients to identify any discrepancies in
the data captured between the groups.
Ethical Issues
The study was approved by the Danish ethics committee
j.nr: 2007-58-0015. Confidentiality and anonymity were
guaranteed to participants before entering the study. All pa-
tients were invited to participate in the study and received
verbal and written information. Patients unable to provide
consent were excluded. Participants could withdraw from the
study at any time.
Study Setting
The study was divided in two parts.
- A point prevalence study carried out among inpatients
at two acute hospitals in Copenhagen, over a period of
4 days.
- Patient identification from four different sites in the
Copenhagen area through professionals was undertaken
over a 4-week period. These services were an acute-
based lymphedema service, primary care nurses in
Copenhagen, primary care nurses in a rural setting, and
a private therapy-led lymphedema service in primary
care.
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Hospital inpatient prevalence study
In addition to ethical approval, permission was granted by
the hospital administration to conduct the study. The head
nurse of each ward was informed in writing about the study
and they received a plan for the time of the visit from the
research team. A list of the number of beds available at each
ward in addition to bed occupancy and a list of current pa-
tients were available. Reasons for patients not being available
at the time of the visit were recorded and reasons for any other
exclusions.
In addition to the main inclusion and exclusion criteria for
the study, the team asked the head nurse to identify any pa-
tient who should not be approached and the reasons for this.
Patients were provided with written information 4 hours
before being approached for consent. Participants were in-
formed that they could withdraw from the study at any time.
Screening for CO
All patients were screened to identify the presence or ab-
sence of CO by the use of a standard assessment, the pitting
edema test, which measures the site and depth of swelling in
an edematous area when pressure is applied by the thumb.
A positive result is indicated if a pit remains following re-
moval of pressure. This is a well-established clinical tech-
nique, but inter-rater reliability was further assessed for its
use in the LIMPRINT study. Levels of agreement were found
to be high between general nurses performing the technique
and a clinical expert (gold standard) in Japan.8 Edema was
judged to be chronic if it had been present for 3 months or
more.
Research Team Preparation
The research team consisted of student nurses who were
supervised by specialist teams from the wound healing center
at Copenhagen and visiting international lymphedema con-
sultants. The specialists were responsible for classification of
patients into a primary or secondary form of lymphedema in
all cases identified with CO. Any participant for whom the
underlying classification of lymphedema was uncertain was
discussed within the expert group and a second clinical as-
sessment was undertaken.
During the study period, small research teams were formed
with experts in each group. All those involved in data col-
lection were educated and were assessed to be competent by
specialists working with them during the first assessment of
participants. Student nurses did not classify patients as cases.
All those involved in data collection received a day of edu-
cation and were assessed using a competency framework.
The inpatients were examined over a 4-day period and data
entered into a paper-based case report form. Due to time and
limited resources, a random permuted block design allowed
for a 50% minimum sample in which additional clinical,
health-related quality-of-life, and disability data were col-
lected.
Quality mechanisms and study monitors were in place to
ensure that data were complete before leaving the clinical
area and to avoid double counting of any participants who
may have moved wards during the study and may have been
screened twice. At the end of each day, data for the day were
checked by an independent quality monitor. After data cap-
ture was complete, they were subsequently entered into the
online electronic data system, which has additional quality
procedures to ensure complete and accurate data.7
Primary care and specialist lymphedema services
Staff in each primary community nursing team screened
their total caseloads for consent and inclusion, irrespective of
the reason for needing nursing care. The study was carried out
by nurses with expert knowledge in wounds and CO. Training
was provided for all sites using the procedures outlined
above. A unique patient identification code was issued for
each patient to avoid double counting, and all questionnaires
were preprinted with participant ID numbers. Master identi-
fier lists were retained by each service manager to ensure that
anonymity was maintained and for data protection purposes.
Two specialist nurses were responsible for assessing the
quality of data and entering into the international database.
Data management and statistical analyses
All data collected were coded before being keyed into a
database designed for the study. The datasheet was stored
securely and destroyed after statistical analyses had been
completed. Information from the database was downloaded
to an Excel file. This file was then uploaded into a standard
statistical package (Stata 12.0; Statcorp). All analyses were
undertaken using univariate comparisons between the
groups. Continuous data were analyzed using a t-test for
comparison. Categorical data were compared using the
Pearson v2 test. Where numbers were small in one or more
cells, Fisher’s exact test was used.
Assessment of Feasibility
At completion of each day during data collection, the study
team met together to discuss any issues they had faced and the
solutions they used when necessary. This included assess-
ment of methods used to screen patients in busy ward set-
tings, difficulties of using the randomization process, and the
practical challenges faced by research teams. A field diary of
these issues was kept by the principal investigator who shared
the overall findings with the international research team who
were able to make additional tools available for participants
in the wider research study.
Results
Hospital inpatient prevalence
Within the potential hospital patient population of 578
patients, 452 were included for screening for CO. From the
total group, 126/578 patients were excluded. The main reason
was being absent from the ward at the time of screening
(n= 76) or an inability to consent due to issues such as de-
mentia (n= 50). Of the total participants (n = 452) who were
screened, 177 (39%) suffered with CO for more than 3
months and 275 (61%) did not.
Lymphedema service and primary care
nursing services
A total of 723 participants with CO were identified through
other services. The specialist lymphedema service identified
410 (57%), primary care nurses in Copenhagen identified 253
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(35%), primary care nurses in a rural setting identified 51
(7%), and 9 (1%) were from a private lymphedema clinic in
the community.
Comparison of age and gender
Table 1 gives details of the age and gender of participants
in all groups. While age was similar between men and women
in the lymphedema service and primary care nursing services
(LSPCs), there was evidence of a substantial difference be-
tween genders in the different services. The age of both
genders was significantly higher in the inpatient group for
both women (<0.001) and men (0.006). There was a slightly
higher proportion of women (55%) in the LSPC group
compared with inpatients (51%), but this did not achieve a
standard level of statistical significance ( p= 0.32).
Level of obesity
As would be expected, there was a proportion of partici-
pants who were either obese or morbidly obese. In the in-
patient group and LSPC group, percentages of patients
considered to be obese or morbidly obese were, respectively,
37% and 35%. Being underweight occurred significantly
more in the inpatient group (12%) compared with only 4% in
the other services. Overall, there was evidence of a significant
difference in distribution of BMI categories ( p < 0.001),
Table 1.
Other comorbidities
There was a high percentage of participants in both groups
with comorbidities associated with CO, Table 1. Heart failure/
ischaemic heart disease was significantly more prevalent in
the inpatient group (45% vs. 23%, p < 0.001) as well as
neurological disease (18% vs. 11% p = 0.009). Similar non-
significant differences were noted for the presence of diabetes
and peripheral artierial occlusive disease. In these numbers,
more than one comorbidity can occur in the individual pa-
tient. There were significantly more patients suffering from at
least one comorbidity (including obesity) in the inpatient
Table 1. Demographic Details and Comorbidities of Participants with Chronic Edema
LPCS Hospital inpatient prevalence
t (df) pN Mean Sd N Mean Sd
Age (women) 390 66.6 18.4 90 76.5 11.8 4.90 (486) <0.001
Age (men) 325 66.4 15.3 87 71.3 12.6 2.75 (410) 0.006
Total 715 177
N % N % v2 (df) p
Gender
Female 398 55.1 90 50.9 1.01 (1) 0.32
Male 325 44.9 87 49.1
Total 723 177
Obesity
Underweight 26 3.6 21 12.0 25.00 (3) <0.001
Normal weight 446 61.7 89 50.9
Obese 192 26.6 56 32.0
Morbidly obese 59 8.2 9 5.1
Total 723 175
Diabetes
Present 144 19.9 43 24.3 1.65 (1) 0.198
Absent 579 80.1 134 75.7
Total 723 177
Heart failure/IHD
Present 169 23.4 79 44.6 32.18 (1) <0.001
Absent 554 76.6 98 55.4
Total 723 177
Neurological disease
Present 79 10.9 32 18.1 6.73 (1) 0.009
Absent 644 89.1 145 81.9
Total 723 177
Peripheral arterial disease
Present 61 8.4 21 11.9 2.01 (1) 0.16
Absent 662 91.6 156 88.1
Total 723 177
‡ one comorbidity 456 63.1 141 79.7 17.52 (1) <0.001
No comorbidity 267 36.9 36 20.3
Total 723 177
IHD, ischaemic heart disease; LPCSs, lymphedema and primary care services.
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group compared with the LSPC group (80% vs. 63%,
p < 0.001).
Classification of lymphedema
Lymphedema was diagnosed and classified as either pri-
mary or secondary from the patient history of CO, Table 2.
There was a significantly higher percentage of patients with
primary lymphedema in the LSPC group (13% vs. 1%). Of
the 175 patients with secondary disease in the inpatient study,
only 1 (0.6%) had cancer-related lymphedema compared
with 55 (9%) in the LSPC group ( p < 0.001). Of the total
number of patients with secondary disease, a significantly
higher proportion had a venous cause in the LSPC group
(69% vs. 41%), while immobility was given as the cause in
more patients in the inpatient population (44% vs. 18%).
There was a substantial minority of patients who were given
other classifications in both groups, but more frequently in
the inpatient study group (23% vs. 14%).
Location and duration of CO
Surprisingly, just over 6% of patients suffered from arm
CO in both groups (Table 3). The difference between groups
became apparent when examining the proportion of patients
with leg and midline CO. More patients were found with
midline CO in the LSPC group (30) compared with none in
the inpatients.
In the inpatient study, we found that 23% of patients had
CO for less than 6 months compared with 10% in the LSPC
group. In those with a duration of 6–12 months and 1–2 years,
the pattern was reversed with a higher percentage being
present in the LSPC group. With longer duration of lym-
phedema, the groups had similar distribution. In both popu-
lations, over 26% had suffered with swelling for more than
10 years.
Infection and hospitalization for CO
We found that 14% of patients in the hospital prevalence of
CO have had an infection in the area of CO (Table 4) and
almost 8% of the cases had this infection within the last year.
In LSPCs, over 30% had a history of infection in the area of
CO, and of the total group, 20% experienced an infection
within the past year. The number of infections varied greatly,
with the majority experiencing one or two infections.
Interestingly, while the number of infections was lower in
the inpatient group, nevertheless, they were more likely to be
admitted to hospital for the infection (11/14 vs. 73/143).
Treatment and control of swelling
In the LSPC group, 83% were receiving some form of
standard lymphedema treatment. This compares with just
27% in the hospital group (Table 5). These differences were
noted for multilayer bandaging (43% vs. 7%), use of a
compression garment (63% vs. 23%), and manual lymphatic
drainage (5% vs. 0%).
Patients within the LSPC group were more likely to ex-
perience good subjective control of their swelling compared
with inpatients (67% vs. 20%). This is perhaps not surprising
given the paucity of treatments being offered to those patients
within the hospital study.
Table 2. Causes of Lymphedema in Participants with Chronic Edema
Classification
LPCS Hospital inpatient prevalence
v2 (df) pN % N %
Primary 94 13.0 2 1.1 21.02 (1) <0.001
Secondary 629 87 175 98.9
Total 723 177
Cancer
Present 55 8.7 1 0.6 <0.001a
Absent 574 91.3 174 99.4
Total 629 175
Venous
Present 437 69.4 71 40.6 49.17 (1) <0.001
Absent 192 30.5 104 59.4
Total 629 175
Immobility
Present 111 17.7 77 44.0 53.07 (1) <0.001
Absent 518 82.3 98 56.0
Total 629 175
Obesity
Present 125 19.9 42 24.0 1.42 (1) 0.23
Absent 504 80.1 133 76.0
Total 629 175
Other
Present 87 13.8 40 22.9 8.39 (1) 0.004
Absent 542 86.2 135 77.1
Total 629 175
aFisher’s exact test.
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Table 3. Location and Duration of Lymphedema in Participants with Chronic Edema
LPCS Hospital inpatient prevalence
v2 (df) pN % N %
Arm (s)
Present 46 6.4 11 6.2 0.005 (1) 0.94
Absent 677 93.6 166 93.8
Total 723 177
Leg (s)
Present 683 94.5 176 99.4 0.002a
Absent 40 5.5 1 0.6
Total 723 177
Midline
Present 30 4.2 0 0.0 0.002a
Absent 693 95.9 177 100.0
Total 723 177
Duration
<6 months 74 10.2 40 22.6 29.10 (5) <0.001
6 months to 1 year 97 13.4 13 7.3
1–2 years 126 17.4 16 9.0
2–5 years 152 21.0 33 18.6
5–10 years 88 12.2 26 14.7
10+ years 186 25.7 49 27.7
Total 723 176
Control of swelling
Yes 469 66.7 35 19.9 126.2 (1) <0.001
No 234 33.3 141 80.1
Total 703 176
aFisher’s exact test.
Table 4. Infections in Participants with Chronic Edema
LPCS Hospital inpatient prevalence
v2 (df) pN % N %
Ever had cellulitis?
Yes 221 30.6 25 14.1 19.35 (1) <0.001
No 502 69.4 152 85.9
Total 723 177
Acute infection in the last year?
Yes 143 19.8 14 7.9 13.90 (1) <0.001
No 580 80.2 163 92.1
Number
1 84 58.7 9 64.3
2 33 23.1 3 21.4
3 11 7.7 1 7.1
4 7 4.9 0 0
5 5 3.5 1 7.1
>5 3 2.1 0 0
Total 723 177
Hospitalized in the last year?
Yes 73 10.1 11 6.2 2.53 (1) 0.11
No 650 89.9 166 93.8
Number
1 58 79.5 8 72.7
2 10 13.7 1 9.1
3 3 4.1 1 9.1
>3 2 2.7 1 9.1
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Random sample [inpatient population N= 116/177
(65.5%)]
Data from the random sample from the hospital inpatient
service indicated that 47/116 (41%) lived alone, with 56/116
(48%) owning their own property. Not surprisingly, given the
age of the sample, 69% were retired with only 5% not
working due to illness. However, 10% stated that the family
income had been affected by having CO, irrespective of their
working status. The majority were defined as having pitting
edema with limb shape distortion evident in 32%.
Feasibility of the methods
The study provided important insights into undertaking the
study in diverse settings. Changes in education for the main
study were made and this included developing a short video
to assess pitting edema, performing a Stemmer test, and
measuring the limb for shape distortion. Quality mechanisms
for ensuring quality data were effective and integrated into
the study standard operating procedures. The validation
process reinforced the hypothesis that classification of lym-
phedema as primary and secondary lymphedema is difficult
even when there is access to trained lymphologists and can-
not be performed reliably in primary care settings.
Discussion
The high prevalence of 39% of hospital inpatients suffer-
ing from CO has not been reported before and indicates that it
is an important problem in hospital settings and is accom-
panied by a range of comorbidities. As admission was gen-
erally unrelated to CO, one might consider that these patients
would be suffering from a mild condition, which does not
require treatment. However, evidence from this study indi-
cates that this is not the case. These patients were elderly with
a range of comorbidities that might predispose them to a
chronic and severe predisposition and the development of
infection and other issues that characterize poor outcome.
Comparison between this group and a group who were
receiving care from a variety of specialist lymphedema ser-
vices and primary care services has identified not only sim-
ilarities but also several differences. As an example, the
inpatient group experienced fewer acute infections than those
managed by the lymphedema services. However, when they
did develop an infection, it more frequently led to hospital-
ization. It is difficult to know quite why this is so, but it is
perhaps indicative of patients within the lymphedema ser-
vices being managed more effectively without the need for
hospital admissions.
Another key element of risk is that of poor mobility. From the
data, it is clear that immobility was cited as a cause of CO more
frequently in those admitted to hospital than those in dedicated
lymphedema services. Again, it is hard to be precise on what is
occurring, but this fits the profile of a more elderly immobile
population receiving suboptimal care in the community. Clearly,
this is speculation, which requires further investigation.
Limitations
The study has some limitations that must be addressed. In
particular, the participants recruited from community-based
lymphedema services and primary care nursing services are
unlikely to be representative of the total population receiving
care within this service, leading to a selection bias. This led
the LIMPRINT study team to develop specific methods to
recruit for community studies to increase reliability and va-
lidity. These have been reported separately.9
Conclusion
This initial validation study highlighted opportunities and
challenges associated with undertaking LIMPRINT in a
Table 5. Treatments for Lymphedema and Control of Swelling
LPCS Hospital inpatient prevalence
v2 (df) pN % N %
None 124 17.1 130 73.5 222.5 (1) <0.001
At least one 599 82.9 47 26.6
Total 723 177
Multilayer bandaging
Present 312 43.2 12 6.8 81.6 (1) <0.001
Absent 411 56.9 165 93.2
Total 723 177
Compression garment
Present 453 62.7 40 22.6 92.1 (1) <0.001
Absent 270 37.4 137 77.4
Total 723 177
Massage
Present 38 5.3 0 0.0 <0.001a
Absent 685 94.7 177 100
Total 723 177
Control of swelling
Yes 469 66.7 35 19.9 126.2 (1) <0.001
No 234 33.3 141 80.1
Total 703 176
aFisher’s exact test.
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different health setting. It led to improvements in the study
methodology and quality mechanisms. The hospital inpatient
study showed the difficulty of gaining consent and accessing
patients in busy hospital settings. Nevertheless, in those re-
cruited, the prevalence of 39% is the highest yet recorded.
Comparison of participant profiles between the inpatient and
other lymphedema specialist services and primary care re-
veals a complex picture of comorbidities that have been ex-
amined further in other LIMPRINT studies.
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